# James C. Yao

Source: https://onco.cc/people/james-yao/  
OnCo record `james-yao` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours.

## Summary

James Yao was principal investigator of RADIANT-3 and RADIANT-4, which established everolimus for progressive pancreatic and then non-functional lung and GI neuroendocrine tumours, and authored the SEER analysis that documented the rising incidence of NETs. He chairs GI medical oncology at MD Anderson and co-led the NET Task Force of the NCI GI steering committee.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: neuroendocrine; mtor; trialist
- Role: Chair, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center
- Specialisms: Neuroendocrine tumours; mTOR inhibitors; Epidemiology; Gastrointestinal oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Yao%20JC%5BAuthor%5D%20neuroendocrine%20everolimus

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [RADIANT-3 and RADIANT-4](https://onco.cc/trials/radiant-3-4/)

---
JSON: https://onco.cc/api/v1/entities/james-yao.json